PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.